MUNICH–(BUSINESS WIRE)– Definiens, the leader in image analysis for digital pathology and diagnostics, announced today that it has appointed Christiaan Neeleman Chief Operating Officer and member of the Executive Board. As COO, he will be responsible for leadership of Research, Development, and Professional Services activities. Neeleman brings 25 years of General Management experience with a focus on healthcare imaging, and his operational expertise will be critical in further expanding the leadership position of Definiens in image analysis.
“Christiaan brings a strong operational background to the company. As we grow our position in life sciences and execute on our roadmap towards clinical digital pathology and diagnostics, a healthcare industry veteran like Christiaan will be an extremely valuable asset to the executive team,” commented Definiens CEO, Thomas Heydler.
Prior to joining Definiens, Christiaan Neeleman held several General Management positions in the Healthcare Imaging industry, most importantly as leader of the X-Ray Systems business for Philips Healthcare.
Ralf Huss, a renowned pathologist and the Chief Medical Officer for Definiens added, “Definiens is rapidly developing solutions for tissue biomarker discovery and digital pathology. While we continue to be the leader in image analysis overall, the addition of Christiaan Neeleman to the team places us in an extremely solid position for our future plans to transform digital pathology.”
Neeleman will be located in Definiens’ Munich Headquarters.
Definiens is the leading provider of image analysis solutions and data mining solutions for life science, tissue diagnostics, and clinical digital pathology. Definiens’ technology provides detailed biomarker readouts from slide images and enables the correlation of this information with other key clinical or genomic information. Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy.
Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine, and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany with a North American headquarters in Carlsbad, CA. Further information is available at www.definiens.com.